Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2 received Fast Track designation from the U.S. Food and Drug Administration (FDA)

A light on the blackhole horizon in the time of coronavirus

NEW YORK and MAINZ, Germany, July 13, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.

Read more

Clinical Trial
NCT04380701
NCT04368728